总览

使用 EasySep™ 人B细胞分离试剂盒，可轻松高效地从新鲜或冻存的人外周血单个核细胞（PBMCs）或白细胞单采术样本中通过免疫磁珠负选获得高纯度的人B细胞。EasySep™技术结合单克隆抗体的特异性和免磁柱系统的简便性，已在发表的研究中广泛应用超过20年。

在该 EasySep™负选流程中，非目的细胞会被抗体复合物与磁珠标记。表达以下标记物的非目的细胞将被靶向去除：CD2、CD3、CD14、CD16、CD36、CD43、CD56、CD66b和 GlyA。通过EasySep™磁极将被磁珠标记的细胞与未被标记的目的细胞分离，只需将目的细胞倾倒或移液至新试管中。磁珠分选最快仅需9分钟，所得目的B细胞即可用于流式细胞术、培养或DNA/RNA提取等下游应用。

该试剂盒可替代EasySep™人B细胞富集试剂盒 (产品号 #19054) 以实现更快速地细胞分选。

如需从白细胞单采术样本中大规模分选人B细胞，请选用大包装（1x10^10细胞）试剂盒（产品号 #100-0971）。

了解更多关于免疫磁珠EasySep™技术的工作原理，或如何通过RoboSep™实现免疫磁珠细胞分选全自动化。或直接选用 EasySep™ 人B细胞分选试剂盒提供的即用型、符合伦理道德的原代人外周血B细胞。探索其他针对您的工作流程优化的产品，包括培养基、补充剂、抗体等。

在该 EasySep™负选流程中，非目的细胞会被抗体复合物与磁珠标记。表达以下标记物的非目的细胞将被靶向去除：CD2、CD3、CD14、CD16、CD36、CD43、CD56、CD66b和 GlyA。通过EasySep™磁极将被磁珠标记的细胞与未被标记的目的细胞分离，只需将目的细胞倾倒或移液至新试管中。磁珠分选最快仅需9分钟，所得目的B细胞即可用于流式细胞术、培养或DNA/RNA提取等下游应用。

该试剂盒可替代EasySep™人B细胞富集试剂盒 (产品号 #19054) 以实现更快速地细胞分选。

如需从白细胞单采术样本中大规模分选人B细胞，请选用大包装（1x10^10细胞）试剂盒（产品号 #100-0971）。

了解更多关于免疫磁珠EasySep™技术的工作原理，或如何通过RoboSep™实现免疫磁珠细胞分选全自动化。或直接选用 EasySep™ 人B细胞分选试剂盒提供的即用型、符合伦理道德的原代人外周血B细胞。探索其他针对您的工作流程优化的产品，包括培养基、补充剂、抗体等。

在该 EasySep™负选流程中，非目的细胞会被抗体复合物与磁珠标记。表达以下标记物的非目的细胞将被靶向去除：CD2、CD3、CD14、CD16、CD36、CD43、CD56、CD66b和 GlyA。通过EasySep™磁极将被磁珠标记的细胞与未被标记的目的细胞分离，只需将目的细胞倾倒或移液至新试管中。磁珠分选最快仅需9分钟，所得目的B细胞即可用于流式细胞术、培养或DNA/RNA提取等下游应用。

该试剂盒可替代EasySep™人B细胞富集试剂盒 (产品号 #19054) 以实现更快速地细胞分选。

如需从白细胞单采术样本中大规模分选人B细胞，请选用大包装（1x10^10细胞）试剂盒（产品号 #100-0971）。

了解更多关于免疫磁珠EasySep™技术的工作原理，或如何通过RoboSep™实现免疫磁珠细胞分选全自动化。或直接选用 EasySep™ 人B细胞分选试剂盒提供的即用型、符合伦理道德的原代人外周血B细胞。探索其他针对您的工作流程优化的产品，包括培养基、补充剂、抗体等。

在该 EasySep™负选流程中，非目的细胞会被抗体复合物与磁珠标记。表达以下标记物的非目的细胞将被靶向去除：CD2、CD3、CD14、CD16、CD36、CD43、CD56、CD66b和 GlyA。通过EasySep™磁极将被磁珠标记的细胞与未被标记的目的细胞分离，只需将目的细胞倾倒或移液至新试管中。磁珠分选最快仅需9分钟，所得目的B细胞即可用于流式细胞术、培养或DNA/RNA提取等下游应用。

该试剂盒可替代EasySep™人B细胞富集试剂盒 (产品号 #19054) 以实现更快速地细胞分选。

如需从白细胞单采术样本中大规模分选人B细胞，请选用大包装（1x10^10细胞）试剂盒（产品号 #100-0971）。

了解更多关于免疫磁珠EasySep™技术的工作原理，或如何通过RoboSep™实现免疫磁珠细胞分选全自动化。或直接选用 EasySep™ 人B细胞分选试剂盒提供的即用型、符合伦理道德的原代人外周血B细胞。探索其他针对您的工作流程优化的产品，包括培养基、补充剂、抗体等。

磁体兼容性
• EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • Easy 50 EasySep™ Magnet (Catalog #18002) • EasyEights™ EasySep™ Magnet (Catalog #18103) • RoboSep™-S (Catalog #21000) • Easy 250 EasySep™ Magnet (Catalog #100-0821)

亚型
细胞分选试剂盒

细胞类型
B 细胞

种属
人

样本来源
Leukapheresis，PBMC

筛选方法
Negative

应用
细胞分选

品牌
EasySep，RoboSep

研究领域
嵌合体，HLA，免疫

查看更多显示更少

实验数据

Figure 1. Typical EasySep™ Human B Cell Isolation Profile

Starting with human PBMCs, the B cell (CD3-CD19+) content of the isolated fraction is typically 95.1 ± 1.4% (mean ± SD). In the example above, the final purities of the start and isolated fractions are 4.5% and 94.9%, respectively.

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。

Document Type

Product Name

Catalog #

Lot #

Language

Document Type

Product Information Sheet

Product Name

EasySep™ Human B Cell Isolation Kit

Catalog #

100-0971

Lot #

All

Language

English

Document Type

Product Information Sheet 1

Product Name

EasySep™ Human B Cell Isolation Kit

Catalog #

17954

Lot #

All other lots

Language

English

Document Type

Product Information Sheet 2

Product Name

EasySep™ Human B Cell Isolation Kit

Catalog #

17954

Lot #

Purchase date 2020-04-07 and later

Language

English

Document Type

Product Information Sheet 1

Product Name

RoboSep™ Human B Cell Isolation Kit

Catalog #

17954RF

Lot #

All other lots

Language

English

Document Type

Product Information Sheet 2

Product Name

RoboSep™ Human B Cell Isolation Kit

Catalog #

17954RF

Lot #

Purchase date 2020-04-07 and later

Language

English

Document Type

Safety Data Sheet 1

Product Name

EasySep™ Human B Cell Isolation Kit

Catalog #

100-0971

Lot #

All

Language

English

Document Type

Safety Data Sheet 2

Product Name

EasySep™ Human B Cell Isolation Kit

Catalog #

100-0971

Lot #

All

Language

English

Document Type

Safety Data Sheet 1

Product Name

EasySep™ Human B Cell Isolation Kit

Catalog #

17954

Lot #

All

Language

English

Document Type

Safety Data Sheet 2

Product Name

EasySep™ Human B Cell Isolation Kit

Catalog #

17954

Lot #

All

Language

English

Document Type

Safety Data Sheet 3

Product Name

EasySep™ Human B Cell Isolation Kit

Catalog #

17954

Lot #

All

Language

English

Document Type

Safety Data Sheet 1

Product Name

RoboSep™ Human B Cell Isolation Kit

Catalog #

17954RF

Lot #

All

Language

English

Document Type

Safety Data Sheet 2

Product Name

RoboSep™ Human B Cell Isolation Kit

Catalog #

17954RF

Lot #

All

Language

English

Document Type

Safety Data Sheet 3

Product Name

RoboSep™ Human B Cell Isolation Kit

Catalog #

17954RF

Lot #

All

Language

English

Document Type

Safety Data Sheet 4

Product Name

RoboSep™ Human B Cell Isolation Kit

Catalog #

17954RF

Lot #

All

Language

English

应用领域

本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。

Research Area

Workflow Stages

Workflow Stages for B Cell Research

Cell Sourcing

Cell Isolation

Cell Expansion

Cell Characterization

Can EasySep™ be used for either positive or negative selection?

Yes. The EasySep™ kits use either a negative selection approach by targeting and removing unwanted cells or a positive selection approach targeting desired cells. Depletion kits are also available for the removal of cells with a specific undesired marker (e.g. GlyA).

How does the separation work?

Magnetic particles are crosslinked to cells using Tetrameric Antibody Complexes (TAC). When placed in the EasySep™ Magnet, labeled cells migrate to the wall of the tube. The unlabeled cells are then poured off into a separate fraction.

Which columns do I use?

The EasySep™ procedure is column-free. That's right - no columns!

How can I analyze the purity of my enriched sample?

The Product Information Sheet provided with each EasySep™ kit contains detailed staining information.

Can EasySep™ separations be automated?

Yes. RoboSep™, the fully automated cell separator, automates all EasySep™ labeling and cell separation steps.

Can EasySep™ be used to isolate rare cells?

Yes. We recommend a cell concentration of 2x10⁸ cells/mL and a minimum working volume of 100 µL. Samples containing 2x10⁷ cells or fewer should be suspended in 100 µL of buffer.

Are the EasySep™ magnetic particles FACS-compatible?

Yes, the EasySep™ particles are flow cytometry-compatible, as they are very uniform in size and about 5000X smaller than other commercially available magnetic beads used with column-free systems.

Can the EasySep™ magnetic particles be removed after enrichment?

No, but due to the small size of these particles, they will not interfere with downstream applications.

Can I alter the separation time in the magnet?

Yes; however, this may impact the kit's performance. The provided EasySep™ protocols have already been optimized to balance purity, recovery and time spent on the isolation.

For positive selection, can I perform more than 3 separations to increase purity?

Yes, the purity of targeted cells will increase with additional rounds of separations; however, cell recovery will decrease.

How does the binding of the EasySep™ magnetic particle affect the cells? is the function of positively selected cells altered by the bound particles?

Hundreds of publications have used cells selected with EasySep™ positive selection kits for functional studies. Our in-house experiments also confirm that selected cells are not functionally altered by the EasySep™ magnetic particles.

If particle binding is a key concern, we offer two options for negative selection. The EasySep™ negative selection kits can isolate untouched cells with comparable purities, while RosetteSep™ can isolate untouched cells directly from whole blood without using particles or magnets.

Chemoproteomic development of SLC15A4 inhibitors with anti-inflammatory activity. T.-Y. Chiu et al. Nature chemical biology 2024 aug

Abstract

SLC15A4 is an endolysosome-resident transporter linked with autoinflammation and autoimmunity. Specifically, SLC15A4 is critical for Toll-like receptors (TLRs) 7-9 as well as nucleotide-binding oligomerization domain-containing protein (NOD) signaling in several immune cell subsets. Notably, SLC15A4 is essential for the development of systemic lupus erythematosus in murine models and is associated with autoimmune conditions in humans. Despite its therapeutic potential, the availability of quality chemical probes targeting SLC15A4 functions is limited. In this study, we used an integrated chemical proteomics approach to develop a suite of chemical tools, including first-in-class functional inhibitors, for SLC15A4. We demonstrate that these inhibitors suppress SLC15A4-mediated endolysosomal TLR and NOD functions in a variety of human and mouse immune cells; we provide evidence of their ability to suppress inflammation in vivo and in clinical settings; and we provide insights into their mechanism of action. Our findings establish SLC15A4 as a druggable target for the treatment of autoimmune and autoinflammatory conditions.

View publication

ATR-mediated DNA damage responses underlie aberrant B cell activity in systemic lupus erythematosus. T. Manolakou et al. Science advances 2022 oct

Abstract

B cells orchestrate autoimmune responses in patients with systemic lupus erythematosus (SLE), but broad-based B cell-directed therapies show only modest efficacy while blunting humoral immune responses to vaccines and inducing immunosuppression. Development of more effective therapies targeting pathogenic clones is a currently unmet need. Here, we demonstrate enhanced activation of the ATR/Chk1 pathway of the DNA damage response (DDR) in B cells of patients with active SLE disease. Treatment of B cells with type I IFN, a key driver of immunity in SLE, induced expression of ATR via binding of interferon regulatory factor 1 to its gene promoter. Pharmacologic targeting of ATR in B cells, via a specific inhibitor (VE-822), attenuated their immunogenic profile, including proinflammatory cytokine secretion, plasmablast formation, and antibody production. Together, these findings identify the ATR-mediated DDR axis as the orchestrator of the type I IFN-mediated B cell responses in SLE and as a potential novel therapeutic target.

View publication

A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma. M. H. Qazilbash et al. Blood 2022 mar

Abstract

We hypothesized that combining adoptively transferred autologous T cells with a cancer vaccine strategy would enhance therapeutic efficacy by adding antimyeloma idiotype (Id)-keyhole limpet hemocyanin (KLH) vaccine to vaccine-specific costimulated T cells. In this randomized phase 2 trial, patients received either control (KLH only) or Id-KLH vaccine, autologous transplantation, vaccine-specific costimulated T cells expanded ex vivo, and 2 booster doses of assigned vaccine. In 36 patients (KLH, n = 20; Id-KLH, n = 16), no dose-limiting toxicity was seen. At last evaluation, 6 (30%) and 8 patients (50%) had achieved complete remission in KLH-only and Id-KLH arms, respectively (P = .22), and no difference in 3-year progression-free survival was observed (59% and 56%, respectively; P = .32). In a 594 Nanostring nCounter gene panel analyzed for immune reconstitution (IR), compared with patients receiving KLH only, there was a greater change in IR genes in T cells in those receiving Id-KLH relative to baseline. Specifically, upregulation of genes associated with activation, effector function induction, and memory CD8+ T-cell generation after Id-KLH but not after KLH control vaccination was observed. Similarly, in responding patients across both arms, upregulation of genes associated with T-cell activation was seen. At baseline, all patients had greater expression of CD8+ T-cell exhaustion markers. These changes were associated with functional Id-specific immune responses in a subset of patients receiving Id-KLH. In conclusion, in this combination immunotherapy approach, we observed significantly more robust IR in CD4+ and CD8+ T cells in the Id-KLH arm, supporting further investigation of vaccine and adoptive immunotherapy strategies. This trial was registered at www.clinicaltrials.gov as #NCT01426828.

View publication

View All Publications

EasySep™人B细胞分选试剂盒

产品号 #（选择产品）

产品号 #17954_C

产品优势

产品组分包括

总览

实验数据

产品说明书及文档

应用领域

相关材料与文献

Request Pricing

更多信息

Scientists Helping Scientists™

种属	Human
Magnet Compatibility	• EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • Easy 50 EasySep™ Magnet (Catalog #18002) • EasyEights™ EasySep™ Magnet (Catalog #18103) • RoboSep™-S (Catalog #21000) • Easy 250 EasySep™ Magnet (Catalog #100-0821)
样本来源	Leukapheresis, PBMC
Selection Method	Negative

EasySep™人B细胞分选试剂盒

产品号 #（选择产品）

产品号 #17954_C

产品优势

产品组分包括

总览

实验数据

产品说明书及文档

应用领域

相关材料与文献

技术资料 (13)

常见问题

Can EasySep™ be used for either positive or negative selection?

How does the separation work?

Which columns do I use?

How can I analyze the purity of my enriched sample?

Can EasySep™ separations be automated?

Can EasySep™ be used to isolate rare cells?

Are the EasySep™ magnetic particles FACS-compatible?

Can the EasySep™ magnetic particles be removed after enrichment?

Can I alter the separation time in the magnet?

For positive selection, can I perform more than 3 separations to increase purity?

How does the binding of the EasySep™ magnetic particle affect the cells? is the function of positively selected cells altered by the bound particles?

文献 (14)

Abstract

Abstract

Abstract

Request Pricing

更多信息

欢迎您关注STEMCELL Technologies的微信公众平台